Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Epilepsy Behav ; 20(4): 725-7, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21411374

RESUMEN

Lacosamide (LCM) is a novel anticonvulsant that modulates voltage-dependent sodium channels. Although it is known to cause a slight, dose-dependent prolongation of the PR interval on the ECG, third-degree atrioventricular (AV) block has been described as an adverse event in only a few patients participating in diabetic neuropathic pain studies and in no patient with epilepsy. We describe an 89-year old patient with decreased renal function and taking two other negative dromotropic agents who accidentally received two intravenous boli of 400 mg LCM within 6 hours. She had a normal PQ interval before and after the first dose of LCM and developed a reversible complete AV block approximately 30 minutes after the second bolus. We conclude that particular caution must be exercised when using very high doses of LCM in patients with significant cardial and renal risk factors.


Asunto(s)
Acetamidas/efectos adversos , Anticonvulsivantes/efectos adversos , Bloqueo Atrioventricular/inducido químicamente , Anciano de 80 o más Años , Anticuerpos/sangre , Electrocardiografía/métodos , Electroencefalografía , Epilepsia/tratamiento farmacológico , Femenino , Humanos , Lacosamida , Receptores de N-Metil-D-Aspartato/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA